The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
Aditya Nair, MBBS, Seth GS Medical College & King Edward Memorial (KEM) Hospital, Mumbai, India, discusses a prospective feasibility study evaluating patient self-administration of bortezomib in multiple myeloma and amyloidosis. He highlights the importance of structured patient and caregiver training, with a relative dose intensity of 97.9% achieved in the per-protocol analysis, and the potential for home administration to reduce travel and improve access to treatment, particularly in low- and middle-income settings. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
